Tumor-associated Hyperinsulinism (Tumor HI)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Tumor-associated Hyperinsulinism (Tumor HI) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT06881992

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatm…

United States16 participantsStarted 2025-04-16

Treatment: Ersodetug

All recent trials (2 shown)

AVAILABLENot Applicable

NCT07262970

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypogly…

Location not specified

Treatment: Ersodetug (9 mg/kg) + SOC